Abstract
Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment of MSI-H/dMMR mCRC, and the BRAF inhibitor encorafenib, in combination with cetuximab, is approved for previously treated BRAF V600E-mutant mCRC. Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with BRAF V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated BRAF V600E-mutant, MSI-H/dMMR mCRC.
Original language | English (US) |
---|---|
Pages (from-to) | 653-663 |
Number of pages | 11 |
Journal | Future oncology (London, England) |
Volume | 20 |
Issue number | 11 |
DOIs | |
State | Published - Apr 1 2024 |
Keywords
- BRAF V600
- cetuximab
- dMMR
- encorafenib
- immunotherapy
- metastatic colorectal cancer
- MSI-H
- pembrolizumab
- targeted therapy
- triplet combination therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research